 Based on its current operating plan, Evoke believes that its existing cash and cash equivalents will provide sufficient cash to fund its operations into the second quarter of 2021, without consideration of the remaining 3.0 million available under its EVERSANA line of credit or potential GIMOTI revenue. Following the approval of GIMOTI, the first and only nasal therapeutic to treat the symptoms of diabetic gastroparesis in adults, we have further improved our capital position in preparation for commercialization, said David Gonyer, R.Ph., President and CEO. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. 